Galapagos NV

Galapagos NV’s TYK2 inhibitor GLPG3667 shows Phase‑3 success for dermatomyositis & lupus, positioning the biotech firm as a key player in innovative autoimmune therapies.

Galapagos NV is taking decisive steps to reinforce its leadership and board, aiming to drive growth and innovation in its therapeutic areas.

Galapagos NV has announced a strategic pivot, including leadership changes and a re-evaluation of its separation plan, as the biotech company navigates financial challenges and explores new business avenues.

Galapagos NV has announced a strategic shift and leadership changes, including a new CEO, as the biotech company re-evaluates its separation plans and explores new opportunities in the biotechnology landscape.